The Valley Desk

Clinical trial reportBloodPublished

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Blood
Published
Subject terms
Humans; Multiple Myeloma; Dexamethasone; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Prognosis; Treatment Outcome; Adult; Aged; Middle Aged; Female; Male
PubMed ID
41060326
PubMed Central ID
PMC12883856
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal